4Liaw YF.On-treatment outcome prediction and adjustment duringchronic hepatitis B therapy:now and future. Antivir T-her . 2009
5Yuen MF.On-treatment outcome prediction and adjustment duringchronic hepatitis B threapy:now and future. Antiviral T-her . 2009
6Hsu CW,Chen YC,Liaw YF,et al.Prolonged efficacy andsafety of 3 years of continuous telbivudine treatment in pooleddata from GLOBE and 015 study in chronic hepatitis B patients. Journal of Hepatology . 2009
7Jia JD,Gane E.Prolonged efficacy and safety of 4 years contin-uous telbivudine treatment in chronic hepatitis B (CHB)pa-tients from GLOBE and 015 studies. Hepatol Int . 2010
8Wang L,Liu F,Liu YD,et al.Stringent cessation criterionresults in better durability of lamivudine treatment:a prospec-tive clinical study in hepatitis B e antigen-positive chronic hepa-titis B patients. Journal of Viral Hepatitis . 2010
9Lai CL,Gane E,Liaw YF,et al.Telbivudine versus lamivudine in patients with chronic hepatitis B. The New England Journal of Medicine . 2007
10Keeffe EB,Dieterich DT,Han SBet al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States:2008update. Clinics in Gastroenterology . 2008
2Hoofnagle JH, Doo E, I.iang TJ, et al. Management of hepatitis B: Summary of a clinical research workshop. Hepatology, 2007, 45:1056-1075.
3Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology, 2007, 45:507-539.
4[1]Chang TT,Lai CL,Chien RN,Guan R,Lim SG,Lee CM,Ng KY,Nicholls GJ,Dent JC,Leung NW.Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.J Gastroenterol Hepatol 2004; 19:1276-1282
5[2]Lok AS,Lai CL,Leung N,Yao GB,Cui ZY,Schiff ER,Dienstag JL,Heathcote EJ,Little NR,Griffiths DA,Gardner SD,Castiglia M.Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Gastroenterology 2003; 125:1714-1722
6[3]Lai CL,Dienstag J,Schiff E,Leung NW,Atkins M,Hunt C,Brown N,Woessner M,Boehme R,Condreay L.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.Clin Infect Dis 2003; 36:687-696
7[4]Liaw YF,Sung JJ,Chow WC,Farrell G,Lee CZ,Yuen H,Tanwandee T,Tao QM,Shue K,Keene ON,Dixon JS,Gray DF,Sabbat J.Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med 2004; 351:1521-1531
8[5]Kanwal F,Gralnek IM,Hays RD,Dulai GS,Spiegel BM,Bozzette S,Asch S.Impact of chronic viral hepatitis on health-related quality of life in HIV:results from a nationally representative sample.Am J Gastroenterol 2005; 100:1984-1994
9[6]Lok AS,Zoulim F,Locarnini S,Mangia A,Niro G,Decraemer H,Maertens G,Hulstaert F,De Vreese K,Sablon E.Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy:evaluation of performance of INNO-LiPA HBV DR assay.J Clin Microbiol 2002; 40:3729-3734
10[7]Hann HW,Jonsson Funk ML,Rosenberg DM,Davis R.Factors associated with response to lamivudine:Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B.J Gastroenterol Hepatol 2005; 20:433-440
8Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
